What is claimed is:

1. A use of Chinese medicine composition in preparation of medicaments for secondary prevention of coronary heart disease (CHD), wherein said Chinese medicine composition comprises *Radix salvia Miltiorrhiza* and *Radix Notoginseng* extract and *Borneol*, wherein weight ratio of the *Radix salvia Miltiorrhiza* and *Radix Notoginseng* extract to the *Borneol* is (8~15):1, wherein weight of *Salvia Miltiorrhiza* and *Panax Notoginseng* extract is the dry weight.

2. According to the use of claim 1, wherein said secondary prevention of CHD is the secondary prevention of angina pectoris CHD.

3. According to the use of claim 2, wherein said secondary prevention of CHD is the secondary prevention of stable angina pectoris CHD.

4. According to the use of claim 3, wherein said secondary prevention of CHD is to increase exercise tolerance in patients with the stable angina pectoris CHD.

5. According to the use of claim 3, wherein said secondary prevention of CHD is to prolong total exercise time in patients with the stable angina pectoris CHD.

6. According to the use of claim 3, wherein said secondary prevention of CHD is to delay the ST-segment depression or prolong its interval in patients with induced stable angina pectoris CHD.

7. According to the use of claim 3, wherein said secondary prevention of CHD is to delay the onset time of angina pectoris or prolong its interval in patients with induced stable angina pectoris CHD.

8. According to the use of claim 3, wherein said secondary prevention of CHD is to reduce the frequency of angina pectoris in patients with stable angina pectoris CHD.

9. According to the use of claim 3, wherein said secondary prevention of CHD is to decrease nitroglycerin consumption in patients with stable angina pectoris CHD.

10. According to the use of claim 3, wherein said secondary prevention of CHD is to improve the life quality in patients with stable angina pectoris CHD.

11. According to the use of claim 3, wherein said Chinese medicine composition is used in combination with β-receptor blockers.

12. According to the use of claim 1, wherein said secondary prevention of CHD is to improve the biochemical parameters as follows: B-type natriuretic peptide (BNP), C-reactive protein (CRP), lipoprotein phospholipase A2 (Lp-PLA2) and

homocysteine (HCY).

13. According to the use of claim 1, wherein said secondary prevention of CHD is to decrease occurrence or reoccurrence of severe vascular events.

14. According to the use of claim 13, wherein said severe vascular event is death.

15. According to the use of claim 13, wherein said severe vascular event is myocardial infarction.

16. According to the use of claim 13, wherein said severe vascular event is ischemia shock.

17. According to the use of claim 13, wherein said severe vascular event is a situation in which coronary artery bypass grafting, percutaneous transluminal coronary angioplasty and angiocardiography is required.

18. According to the use of claim 13, wherein said Chinese medicine composition is used in combination with antiplatelet agents.

19. According to the use of claim 18, wherein said antiplatelet agent is aspirin.

20. According to any one the use of claims 1~19, wherein said Chinese medicine composition comprises *Radix salvia Miltiorrhiza* & *Radix Notoginseng* extract and *Beoneol* in a weight ratio of (9~10):1, wherein weight of *Radix salvia Miltiorrhiza* & *Radix Notoginseng* extract is the dry weight.

21. According to the use of claim 20, wherein said *Radix salvia Miltiorrhiza* & *Radix Notoginseng* extract is prepared by extracting *Radix salvia Miltiorrhiza* and *Radix Notoginseng* simultaneously, and weight ratio of crude drugs of *Radix salvia Miltiorrhiza* and *Radix Notoginseng*, which are used as starting materials, is (3~7):1.

22. According to the use of claim 21, wherein said weight ratio of crude drugs of *Radix salvia Miltiorrhiza* and *Radix Notoginseng*, which are used as starting materials, is (4~6):1.

23. According to the use of claim 22, wherein said weight ratio of crude drugs of *Radix salvia Miltiorrhiza* and *Radix Notoginseng*, which are used as starting materials, is 5:1.

24. According to the use of claim 23, wherein said crude drugs of *Radix salvia Miltiorrhiza* and *Radix Notoginseng* are extracted with weak alkali aqueous solution.

25. According to the use of claim 24, wherein said *Radix salvia Miltiorrhiza* & *Radix Notoginseng* extract is prepared by a method comprising:
a. extracting pulverized *Radix salvia Miltiorrhiza* and *Radix Notoginseng* with water or weak alkali aqueous solution for 2~3 times, in an amount of 4~8 times the weight of the *Radix salvia Miltiorrhiza* and *Radix Notoginseng* for each time; filtering, combining and properly concentrating the filtrate;
b. performing alcohol precipitation by adding high concentration alcohol into the concentrated solution to make a final alcohol concentration of 50~85% (v/v), standing still to perform precipitation, filtering the supernatant, recovering alcohol from the obtained supernatant and concentrating to give the extract.

26. According to the use of claim 25, wherein said Chinese medicine composition is prepared into a dripping pill, and said dripping pill is prepared with aforesaid composition and adjuvant, wherein said adjuvant is PEG-6000, and the weight ratio of said composition to said adjuvant is (0.2~0.8):1.

27. According to the use of claim 26, wherein said Chinese medicine composition is prepared into a dripping pill, and said dripping pill is prepared with aforesaid composition and adjuvant, wherein said adjuvant is PEG-6000, and the weight ratio of said composition to said adjuvant is (0.29~0.7):1.

28. According to the use of claim 27, wherein said Chinese medicine composition is prepared into a dripping pill, and said dripping pill is prepared with aforesaid composition and adjuvant, wherein said adjuvant is PEG-6000, and the weight ratio of said composition to said adjuvant is (0.5~0.6):1.

What is claimed is:

1. Use of Chinese medicine composition in the preparation of a medicament for the secondary prevention of stable angina pectoris coronary heart disease (CHD), wherein said Chinese medicine composition comprises *Radix salvia Miltiorrhiza* and *Radix Notoginseng* extract and *Borneol*, wherein weight ratio of the *Radix salvia Miltiorrhiza* and *Radix Notoginseng* extract to the *Borneol* is (8~15):1, wherein weight of *salvia Miltiorrhiza* and *Radix Notoginseng* extract is the dry weight; and wherein said *Radix salvia Miltiorrhiza* and *Radix Notoginseng* extract is prepared by extracting *Radix salvia Miltiorrhiza* and *Radix Notoginseng* simultaneously.

2. The use according to claim 1, to increase exercise tolerance in patients with the stable angina pectoris CHD.

3. The use according to claim 1, to prolong total exercise time in patients with the stable angina pectoris CHD.

4. The use according to claim 1, to delay the ST-segment depression or prolong its interval in patients with induced stable angina pectoris CHD.

5. The use according to claim 1, to delay the onset time of angina pectoris or prolong its interval in patients with induced stable angina pectoris CHD.

6. The use according to claim 1, to reduce the frequency of angina pectoris in patients with stable angina pectoris CHD.

7. The use according to claim 1, to decrease nitroglycerin consumption in patients with stable angina pectoris CHD.

8. The use according to claim 1, to improve the life quality in patients with stable angina pectoris CHD.

9. The use according to claim 1, wherein said Chinese medicine composition is used in combination with β-receptor blockers.

10. The use according to claim 1, to improve the biochemical parameters selected from the group consisting of : B-type natriuretic peptide (BNP), C-reactive protein (CRP), lipoprotein phospholipase A2 (Lp-PLA2) and homocysteine (HCY).

11. The use according to claim 1, to decrease occurrence or reoccurrence of severe vascular events.

12. The use according to claim 11, wherein said severe vascular event is death.

13. The use according to claim 11, wherein said severe vascular event is myocardial infarction.

14. The use according to claim 11, wherein said severe vascular event is ischemia shock.

15. The use according to claim 11, wherein said severe vascular event is a situation in which coronary artery bypass grafting, percutaneous transluminal coronary angioplasty and angiocardiography is required.

16. The use according to claim 11, wherein said Chinese medicine composition is used in combination with antiplatelet agents.

17. The use according to claim 16, wherein said antiplatelet agent is aspirin.

18. The use according to any one of claims 1 to17, wherein said Chinese medicine composition comprises *Radix salvia Miltiorrhiza* and *Radix Notoginseng* extract and *Beoneol* in a weight ratio of (9~10):1, wherein weight of *Radix salvia Miltiorrhiza* and *Radix Notoginseng* extract is the dry weight.

19. The use according to claim 18, wherein said *Radix salvia Miltiorrhiza* and *Radix Notoginseng* extract is prepared by extracting *Radix salvia Miltiorrhiza* and *Radix Notoginseng* simultaneously, and weight ratio of crude drugs of *Radix salvia Miltiorrhiza* and *Radix Notoginseng*, which are used as starting materials, is (3~7):1.

20. The use according to claim 19, wherein said weight ratio of crude drugs of *Radix salvia Miltiorrhiza* and *Radix Notoginseng*, which are used as starting materials, is (4~6):1.

21. The use according to claim 20, wherein said weight ratio of crude drugs of *Radix salvia Miltiorrhiza* and *Radix Notoginseng*, which are used as starting materials, is 5:1.

22. The use according to claim 21, wherein said crude drugs of *Radix salvia Miltiorrhiza* and *Radix Notoginseng* are extracted with weak alkali aqueous solution.

23. The use according to claim 22, wherein said *Radix salvia Miltiorrhiza* and *Radix Notoginseng* extract is prepared by a method comprising:
extracting pulverized *Radix salvia Miltiorrhiza* and *Radix Notoginseng* with water or weak alkali aqueous solution for 2~3 times, in an amount of 4~8 times the weight of the *Radix salvia Miltiorrhiza* and *Radix Notoginseng* for each time; filtering, combining and properly concentrating the filtrate;
performing alcohol precipitation by adding high concentration alcohol into the concentrated solution to make a final alcohol concentration of 50~85% (v/v), standing still to perform precipitation, filtering the supernatant, recovering alcohol from the

obtained supernatant and concentrating to give the extract.

24. The use according to claim 23, wherein said Chinese medicine composition is prepared into a dripping pill, and said dripping pill is prepared with aforesaid composition and adjuvant, wherein said adjuvant is PEG-6000, and the weight ratio of said composition to said adjuvant is (0.2~0.8):1.

25. The use according to claim 24, wherein said Chinese medicine composition is prepared into a dripping pill, and said dripping pill is prepared with aforesaid composition and adjuvant, wherein said adjuvant is PEG-6000, and the weight ratio of said composition to said adjuvant is (0.29~0.7):1.

26. The use according to claim 24, wherein said Chinese medicine composition is prepared into a dripping pill, and said dripping pill is prepared with aforesaid composition and adjuvant, wherein said adjuvant is PEG-6000, and the weight ratio of said composition to said adjuvant is (0.5~0.6):1.